A leading RNAi therapeutics company.

Alnylam Pharmaceuticals reviews significant improvement in discovery of novel technologies for systemic delivery of RNAi therapeutics Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, and collaborators from the Massachusetts Institute of Technology , The University of British Columbia , AlCana Technology, Inc., and Tekmira Pharmaceuticals Corporation, presented results from multiple ongoing study efforts concerning the discovery of novel systems for the systemic delivery of RNAi therapeutics. A total of 12 oral posters and presentations were presented at the International Liposome Analysis Days and Lipids, Liposomes & Membrane Biophysics conference kept at UBC in Vancouver, Canada, 4-8 August, 2010.Secondary and exploratory endpoints shall include pain at rest, pain with knee flexibility, level and rate of practical recovery, opioid consumption and security assessments. Further information on the study are available at Related StoriesExpanded make use of for IntelliCap with additional CE Tag for aspiration of fluidsLiposomal sizing and the Coulter theory: an interview with Professor Melvin E. KlegermanSpotting the symptoms of advanced prostate cancer tumor: an interview with Brian Tomlinson ‘While many widely used pain therapies require do it again dosing for indicator amelioration, or require weighty dosing with linked side-effects to treat pain with movement, an individual administration of AYX1 gets the potential to block the development of discomfort before it begins,’ stated Donald Manning , M.D., Ph.D., chief medical officer of Adynxx.

You may also like